Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129


RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma.

Yu F, Gao W, Yokochi T, Suenaga Y, Ando K, Ohira M, Nakamura Y, Nakagawara A.

Oncogene. 2014 May 15;33(20):2601-9. doi: 10.1038/onc.2013.221.


Neuroblastoma cell proliferation is sensitive to changes in levels of RUNX1 and RUNX3 protein.

Inoue K, Ito Y.

Gene. 2011 Nov 10;487(2):151-5. doi: 10.1016/j.gene.2011.05.016.


Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.

Kaneko Y, Suenaga Y, Islam SM, Matsumoto D, Nakamura Y, Ohira M, Yokoi S, Nakagawara A.

Cancer Sci. 2015 Jul;106(7):840-7. doi: 10.1111/cas.12677.


ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.

Wang Q, Hii G, Shusterman S, Mosse Y, Winter CL, Guo C, Zhao H, Rappaport E, Hogarty MD, Maris JM.

Cancer Res. 2003 Apr 1;63(7):1631-5.


The MYCN enigma: significance of MYCN expression in neuroblastoma.

Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung NK, Seeger RC, Evans AE, Ikegaki N.

Cancer Res. 2006 Mar 1;66(5):2826-33.


Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.

Li Y, Zhang B, Zhang H, Zhu X, Feng D, Zhang D, Zhuo B, Li L, Zheng J.

J Cancer Res Clin Oncol. 2013 Jun;139(6):933-41. doi: 10.1007/s00432-013-1406-4.


Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.

Tajiri T, Liu X, Thompson PM, Tanaka S, Suita S, Zhao H, Maris JM, Prendergast GC, Hogarty MD.

Clin Cancer Res. 2003 Aug 15;9(9):3345-55.


Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.

Torres J, Regan PL, Edo R, Leonhardt P, Jeng EI, Rappaport EF, Ikegaki N, Tang XX.

Int J Oncol. 2010 Oct;37(4):983-91.


NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.

Suenaga Y, Islam SM, Alagu J, Kaneko Y, Kato M, Tanaka Y, Kawana H, Hossain S, Matsumoto D, Yamamoto M, Shoji W, Itami M, Shibata T, Nakamura Y, Ohira M, Haraguchi S, Takatori A, Nakagawara A.

PLoS Genet. 2014 Jan;10(1):e1003996. doi: 10.1371/journal.pgen.1003996.


Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.

Smith AG, Popov N, Imreh M, Axelson H, Henriksson M.

J Cell Biochem. 2004 Aug 15;92(6):1282-95.


Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.

Tajiri T, Tanaka S, Higashi M, Kinoshita Y, Takahashi Y, Tatsuta K, Suita S.

J Pediatr Surg. 2006 Mar;41(3):560-6.


MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.

Cortés C, Kozma SC, Tauler A, Ambrosio S.

Cell Oncol (Dordr). 2015 Oct;38(5):341-52. doi: 10.1007/s13402-015-0233-9.


Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.

Chevrier L, Meunier AC, Cochaud S, Muller JM, Chadéneau C.

Int J Oncol. 2008 Nov;33(5):1081-9.


p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.

Dreidax D, Bannert S, Henrich KO, Schröder C, Bender S, Oakes CC, Lindner S, Schulte JH, Duffy D, Schwarzl T, Saadati M, Ehemann V, Benner A, Pfister S, Fischer M, Westermann F.

Hum Mol Genet. 2014 Dec 20;23(25):6826-37. doi: 10.1093/hmg/ddu406.


Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN.

Teitz T, Wei T, Liu D, Valentine V, Valentine M, Grenet J, Lahti JM, Kidd VJ.

Oncogene. 2002 Mar 14;21(12):1848-58.


Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.

Henriksen JR, Haug BH, Buechner J, Tømte E, Løkke C, Flaegstad T, Einvik C.

BMC Dev Biol. 2011 Jan 3;11:1. doi: 10.1186/1471-213X-11-1.


NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.

Hossain S, Takatori A, Nakamura Y, Suenaga Y, Kamijo T, Nakagawara A.

Cancer Res. 2012 Sep 1;72(17):4587-96. doi: 10.1158/0008-5472.CAN-12-0943.


Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.

Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, Valentijn LJ.

Cancer Lett. 2007 Oct 28;256(2):218-28.


Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.

Akter J, Takatori A, Hossain MS, Ozaki T, Nakazawa A, Ohira M, Suenaga Y, Nakagawara A.

Clin Cancer Res. 2011 Nov 1;17(21):6681-92. doi: 10.1158/1078-0432.CCR-11-0313.


Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.

Tanaka S, Tajiri T, Noguchi S, Shono K, Ihara K, Hara T, Suita S.

J Pediatr Surg. 2004 Jan;39(1):63-8.

Items per page

Supplemental Content

Support Center